Loading
The studies needed before a first human trial cost a few million and no grant pays for them. A dedicated fund would decide in weeks and take a small share of any future revenue.
A revolving fund, capitalised by philanthropy and public money, that pays for GLP toxicology, CMC development, formulation and regulatory writing for academic oncology candidates that have passed independent replication of the efficacy result the candidate rests on. Decisions in eight weeks by a standing expert panel; awards of $2 to $8 million; in return the fund takes a low single-digit royalty or a share of licensing revenue, recycled into the fund. Structured like the Wellcome Trust's Seeding Drug Discovery or the Michael J. Fox Foundation's therapeutic pipeline programme, but oncology-focused and paired with the translational institutes. Most academic assets stall exactly here because IND-enabling work is neither science (so not fundable by grants) nor de-risked enough for companies.
Shares A phase 0 fund to test academic compounds in humans with microdoses and imaging, The valley of death between lab and product.
Shares A diversified royalty pool that finances academic phase 1 trials across fifty assets, A phase 0 fund to test academic compounds in humans with microdoses and imaging, The valley of death between lab and product.
Shares Public co-investment in first-in-class phase 1 with a royalty return, The valley of death between lab and product.
Shares Public co-investment in first-in-class phase 1 with a royalty return, The valley of death between lab and product.
Shares Set aside 3% of grant budgets to replicate findings before translation, The valley of death between lab and product.
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.